{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:13:56Z","timestamp":1683504836495},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/bf03347206","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T08:20:16Z","timestamp":1396426816000},"page":"371-378","source":"Crossref","is-referenced-by-count":3,"title":["Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR"],"prefix":"10.1007","volume":"28","author":[{"given":"L.","family":"Tauchmanov\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pensabene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Spagnoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zeppa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mainenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Contegiacomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"key":"BF03347206_CR1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","volume":"340","author":"MH Kulke","year":"1999","unstructured":"Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999, 340: 858\u201368.","journal-title":"N Engl J Med"},{"key":"BF03347206_CR2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","volume":"79","author":"IM Modlin","year":"1997","unstructured":"Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997, 79: 813\u20138.","journal-title":"Cancer"},{"key":"BF03347206_CR3","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1054\/bjoc.2000.1394","volume":"83","author":"F Levi","year":"2000","unstructured":"Levi F, Te VC, Randimbision L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974\u201397. Br J Cancer 2000, 83: 952\u20135.","journal-title":"Br J Cancer"},{"key":"BF03347206_CR4","first-page":"3","volume":"17","author":"J Soga","year":"1998","unstructured":"Soga J. Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res 1998, 17: 3\u201312.","journal-title":"J Exp Clin Cancer Res"},{"key":"BF03347206_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9440(10)65289-3","volume":"154","author":"B G\u00f6trtz","year":"1999","unstructured":"G\u00f6trtz B, Roth J, Krahenmann A, et al. Mutations and allelic deletions of the MEN 1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999, 154: 429\u201336.","journal-title":"Am J Pathol"},{"key":"BF03347206_CR6","first-page":"907","volume":"142","author":"D Lohmann","year":"1993","unstructured":"Lohmann D, Putz B, Reich U, Bohm J, Prauer H, Hofler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 1993, 142: 907\u201315.","journal-title":"Am J Pathol"},{"key":"BF03347206_CR7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","volume":"363","author":"LM Muligan","year":"1993","unstructured":"Muligan LM, Kwok JB, Healey CS, et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363: 458\u201360.","journal-title":"Nature"},{"key":"BF03347206_CR8","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/jnci\/89.19.1448","volume":"89","author":"AO Vortmeyer","year":"1997","unstructured":"Vortmeyer AO, Lubensky IA, Erino MJ, et al. Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Nat Cancer Inst 1997, 89: 1448\u201353.","journal-title":"J Nat Cancer Inst"},{"key":"BF03347206_CR9","first-page":"295","volume-title":"Pathology of the Gastrointestinal Tract","author":"E Solcia","year":"1998","unstructured":"Solcia E, Cappella C, Fiocca R, Sessa F, La Rosa S, Rindi G. Disorders of the endocrine system. In: Williams & Wilkins eds. Pathology of the Gastrointestinal Tract, HGSC Ming. Philadelphia. 1998, 295\u2013322."},{"key":"BF03347206_CR10","first-page":"1","volume-title":"World Health Organization International Histological Classification of tumors. Histological typing of neuroendocrine tumors","author":"E Solcia","year":"2000","unstructured":"Solcia E, Kl\u00f6ppel G, Sobin LH. World Health Organization International Histological Classification of tumors. Histological typing of neuroendocrine tumors. 2nd ed. Berlin, Heidelberg: Springer-Verlag. 2000, 1\u20135.","edition":"2nd"},{"key":"BF03347206_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1040-8428(00)00073-1","volume":"37","author":"E Mitry","year":"2001","unstructured":"Mitry E, Rougier P. The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol 2001, 37: 47\u201351.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BF03347206_CR12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1677\/erc.0.0100459","volume":"10","author":"JES Ardill","year":"2003","unstructured":"Ardill JES, Erikkson B. The importance of the measurement of circulationg markers in patients with neuroendocrine tumors of the pancreas and gut. Endocr Relat Cancer 2003, 10: 459\u201362.","journal-title":"Endocr Relat Cancer"},{"key":"BF03347206_CR13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1677\/erc.0.010a425","volume":"10","author":"M Caplin","year":"2003","unstructured":"Caplin M, Wiedenmann B. The management of patients with neuroendocrine tumors. Endocr Relat Cancer 2003, 10: 425\u20136.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"BF03347206_CR14","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/annonc\/12.suppl_2.S47","volume":"12","author":"GA Kaltsas","year":"2001","unstructured":"Kaltsas GA, Mukherjee JJ, Gossman AB. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumors. Ann Oncol 2001,12 (Suppl 2): S47\u201350.","journal-title":"Ann Oncol"},{"key":"BF03347206_CR15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","volume":"25","author":"GA Kaltsas","year":"2004","unstructured":"Kaltsas GA, Bessere M, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458\u2013511.","journal-title":"Endocr Rev"},{"key":"BF03347206_CR16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, et al. Octreatide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999, 17: 600\u20136.","journal-title":"J Clin Oncol"},{"key":"BF03347206_CR17","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/hmg\/6.7.1169","volume":"6","author":"SK Agarwal","year":"1997","unstructured":"Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997, 6: 1169\u201375.","journal-title":"Hum Mol Genet"},{"key":"BF03347206_CR18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2","volume":"28","author":"LV Debelenko","year":"2000","unstructured":"Debelenko LV, Swalwell JI, Kelley MJ, et al. MEN 1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 2000, 28: 58\u201365.","journal-title":"Genes Chromosomes Cancer"},{"key":"BF03347206_CR19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-109-5-364","volume":"109","author":"HD Hainsworth","year":"1988","unstructured":"Hainsworth HD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly recognized clinicopathologic entity. Ann Int Med 1988, 109: 364\u201371.","journal-title":"Ann Int Med"},{"key":"BF03347206_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1677\/erc.0.0100463","volume":"10","author":"D O\u2019Toole","year":"2003","unstructured":"O\u2019Toole D, Maire F, Ruszniewski P. Ablative therapies forliver metastases of digestive endocrine tumors. Endocr Relat Cancer 2003, 10: 463\u20138.","journal-title":"Endocr Relat Cancer"},{"key":"BF03347206_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00198436","volume":"429","author":"S Rosa La","year":"1996","unstructured":"La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 1996, 429: 323\u201333.","journal-title":"Virchows Arch"},{"key":"BF03347206_CR22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0016-5085(99)70174-5","volume":"116","author":"G Rindi","year":"1999","unstructured":"Rindi G, Azzoni C, La Rosa S, et al. 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999, 116: 532\u201342.","journal-title":"Gastroenterology"},{"key":"BF03347206_CR23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00001622-200201000-00008","volume":"14","author":"K Oberg","year":"2002","unstructured":"Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002, 14: 38\u201345.","journal-title":"Curr Opin Oncol"},{"key":"BF03347206_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0110001","volume":"11","author":"MT Barakat","year":"2004","unstructured":"Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumors. Endocr Relat Cancer 2004, 11: 1\u201318.","journal-title":"Endocr Relat Cancer"},{"key":"BF03347206_CR25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199908263410902","volume":"341","author":"JA Norton","year":"1999","unstructured":"Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999, 341: 635\u201344.","journal-title":"N Engl J Med"},{"key":"BF03347206_CR26","first-page":"227","volume":"68","author":"CG Moertel","year":"1991","unstructured":"Moertel CG, Knolsk LK, O\u2019Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991, 68: 227\u201332.","journal-title":"Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer"},{"key":"BF03347206_CR27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry E, Baudin E, Ducreaux M, et al. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin. Br J Cancer 1999, 81: 1351\u20135.","journal-title":"Br J Cancer"},{"key":"BF03347206_CR28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","volume":"92","author":"ML Fjallskog","year":"2001","unstructured":"Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001, 92: 1101\u20137.","journal-title":"Cancer"},{"key":"BF03347206_CR29","first-page":"290","volume":"52","author":"M Ducreux","year":"2002","unstructured":"Ducreux M, Baudin E, Schlumberger M. Treatment strategy of neuroendocrine tumors. Rev Prat 2002, 52: 290\u20136.","journal-title":"Rev Prat"},{"key":"BF03347206_CR30","first-page":"3","volume-title":"The Expanding Role of Octreotide I: Advances in Oncology","author":"G Ferjoux","year":"2002","unstructured":"Ferjoux G, Torrisani J, Buscail L, Pradayrol L, Susini C. Somatostatin receptors and cancer: antioncogenic role of sst2A. In: SWJ Lamberts and L Dogliotti eds. The Expanding Role of Octreotide I: Advances in Oncology. Bristol: BioScientifica Ltd. 2002, 3\u201315."},{"key":"BF03347206_CR31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","volume":"12","author":"SWJ Lamberts","year":"1991","unstructured":"Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991, 12: 450\u201382.","journal-title":"Endocr Rev"},{"key":"BF03347206_CR32","first-page":"17","volume-title":"The Expanding Role of Octreotide I: Advances in Oncology","author":"DJ Kwekkeboom","year":"2002","unstructured":"Kwekkeboom DJ, Krenning EP. Somatostatin receptors imaging. In: SWJ Lamberts and L Dogliotti eds. The Expanding Role of Octreotide I: Advances in Oncology. Bristol: BioScientifica Ltd. 2002, 17\u201330."},{"key":"BF03347206_CR33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.1998.00373.x","volume":"48","author":"W Shi","year":"1998","unstructured":"Shi W, Buchanan KD, Johnston CF, et al. The octreoscan suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumors correlate with responsiveness to somatostatin analogue treatment. Clin Endocrinol (Oxf) 1998, 48: 303\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03347206_CR34","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","volume":"12S2","author":"K Oberg","year":"2001","unstructured":"Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001, 12 S2: S111\u20134.","journal-title":"Ann Oncol"},{"key":"BF03347206_CR35","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","volume":"37","author":"T Aparicio","year":"2001","unstructured":"Aparicio T, Ducreux M, Baudin E, et al. Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors. Eur J Cancer 2001, 37: 1014\u20139.","journal-title":"Eur J Cancer"},{"issue":"1","key":"BF03347206_CR36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000051863","volume":"62","author":"European Neuroendocrine Tumor Network ENET.","year":"2000","unstructured":"European Neuroendocrine Tumor Network (ENET). Role of somatostatin analogues in oncology. Round Table Discussion: Innsbruck, Austria, February 24\u201327 2000. Digestion 2000, 62 (Suppl 1): 98\u2013107.","journal-title":"Digestion"},{"key":"BF03347206_CR37","first-page":"495","volume":"47","author":"CH Dejong","year":"2002","unstructured":"Dejong CH, Parks RW, Currie E, Piris J, Redhead DN, Garden OJ. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience. J R Coll Surg Edinb 2002, 47: 495\u20139.","journal-title":"J R Coll Surg Edinb"},{"key":"BF03347206_CR38","first-page":"81","volume-title":"The expanding role of Octreotide I: Advances in Oncology","author":"L Dogliotti","year":"2002","unstructured":"Dogliotti L, Brizzi MP, Berruti A, et al. A new approach in the medical treatment of neuroendocrine tumors \u2014 5-fluorouracil continuous infusion plus octreotide-LAR: a feasibility study. In: SW Lamberts and Dogliotti eds. The expanding role of Octreotide I: Advances in Oncology. Bristol: BioScientifica Ltd. 2002, 81\u20138."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03347206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03347206\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03347206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:48:24Z","timestamp":1565311704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03347206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["BF03347206"],"URL":"https:\/\/doi.org\/10.1007\/bf03347206","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}